Vitana X : Q1 Report - VITX_Quarter FS_October 31, 2021

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Three months ended October 31, 2021 and 2020

(Unaudited)

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Three months ended October 31, 2021 and 2020

(Unaudited)

CONTENTS
Consolidated Interim Balance Sheets	3
Consolidated Interim Statement of Operations	4
Consolidated Interim Statement of Changes in Shareholders' Equity (Deficit)	5
Consolidated Interim Statement of Cash Flows	6
Notes to the Consolidated Interim Financial Statements	7

2

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM BALANCE SHEETS Three months ended October 31, 2021 and 2020 (Unaudited)

		October 31,	July 31,
in USD	Notes	2021	2021

ASSETS

CURRENT ASSETS

Cash and cash equivalents

Receivables due from credit card processor

Inventory

Other current receivables due from related parties

Other current assets

TOTAL CURRENT ASSETS

	NON-CURRENT ASSETS
	Fixed assets (net of depreciation)
	Intangible assets (net of amortization)	4
	TOTAL NON-CURRENT ASSETS
	TOTAL ASSETS
	LIABILITIES AND STOCKHOLDERS' DEFICIT
	CURRENT LIABILITIES
	Accounts payable
	Financial liabilities	5
	Provisions
	Other current liabilities
	TOTAL CURRENT LIABILITIES
	NON-CURRENT LIABILITIES
	Financial liabilities	5
	Financial liabilities due to directors			5
	Financial liabilities - Convertible notes payable	5
	TOTAL NON-CURRENT LIABILITIES
	TOTAL LIABILITIES
	STOCKHOLDERS' DEFICIENCY
	Series A Preferred Stock; $0.0001 par value; 1,000,000 designated;	6.3
	1,000,000 shares issued (July 31, 2021: NIL)
	Series B Preferred Stock; $0.0001 par value; 1,344,756 shares designated;			6.4
	NIL shares issued (July 31, 2021: 1,344,756 )
	Common Stock; $0.0001 par value; 5,000,000,000 shares authorized;	6.1
	2,968,279,672 shares issued (July 31, 2021: 1,366,002,045)
	Additional paid-in capital
	Reserve for unissued shares
	Cumulative translation adjustment
	Accumulated deficit
	TOTAL STOCKHOLDERS' DEFICIT
	TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

	27,146			23,035
	29,366			40,019
	464,602			434,250
	75,424			74,553
	51,581			36,702
	648,119			608,559
	35,648			40,525
	56,933			170,799
	92,581			211,324
	740,700			819,883
	267,000			342,001
	181,501			191,252
	223,234			224,563
	168,536			157,739
	840,271			915,555
	129,920			135,224
	181,974			-
	91,568			297,473
	403,462			432,697
	1,243,733			1,348,252
	100		-
				134
	-
	296,828		136,600
	3,952,142			2,185,778
	739,316			2,166,314
	(5,102)			(5,906)
	(5,486,317)			(5,011,289)
	(503,033)			(528,369)
	740,700			819,883

See accompanying notes to the consolidated interim financial statements (unaudited).

3

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM STATEMENT OF OPERATIONS

Three months ended October 31, 2021 and 2020

(Unaudited)

			Three months ended October 31,
	in USD	Notes	2021	2020
	Revenues		301,519		-
	Cost of goods sold		(210,223)		-
	Gross profit		91,296		-
	Operating expenses
	General and administrative		299,475		19,209
	Depreciation and amortization	4	116,060		-
	Professional fees		230,902		233,150
	Total operating expenses		646,437		252,359
	LOSS FROM OPERATIONS		(555,141)		(252,359)
	Other income (expenses)
	Fair value changes of derivative financial instruments		-		255,399
	Gain (loss) from foreign currency transactions		(1,495)		-
	Other financial expenses		(3,892)		-
	Total Other Income (Expenses)		(5,387)		255,399
	NET LOSS		(560,528)		3,040
	NET LOSS PER COMMON SHARE	7
	Basic and diluted		(0.00)		0.00
	Weighted average number of shares outstanding		2,064,859,167		1,260,038,783

See accompanying notes to the consolidated interim financial statements (unaudited).

4

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)

Three months ended October 31, 2021 and 2020

(Unaudited)

								Additional	Reserve for	Cumulative		Total
		Series A Preferred	Series B Preferred	Common Stock	Paid-in	Unissued	Translation	Accumulated	Shareholders'
in USD	Notes	Number	Amount	Number	Amount	Number	Amount	Capital	Shares	Adjustment	Deficit	Deficit
Balance at July 31, 2021		-	-	1,344,756	134	1,366,002,045	136,600	2,185,778	2,166,314	(5,906)	(5,011,289)	(528,369)
Net loss for the interim period		-	-	-	-	-	-	-	-	-	(560,528)	(560,528)
Foreign currency translation		-	-	-	-	-	-	-	-	804	-	804
Total other comprehensive income		-	-	-	-	-	-	-	-	804	(560,528)	(559,724)

Issuance of Series A Preferred Stock for previous period transactions

Issuance of Common Stock for conversion of notes

Exchange of Series B Preferred Stock for Common Stock

Cash received for the issuance of Common Stock

Common Stock granted for services

Settlement of convertible notes

6.3	1,000,000	100	-	-	-	-	-	(100)	-	-	-
6.1	-	-	-	-	714,722,430	71,472	1,854,986	(1,926,458)	-	-	-
6.1	-	-	(1,344,756)	(134)	887,555,197	88,756	(88,622)	-	-	-	-
6.1	-	-	-	-	-	-	-	298,655	-	-	298,655
6.1	-	-	-	-	-	-	-	-	-	85,500	85,500
5	-	-	-	-	-	-	-	200,905	-	-	200,905

Balance at October 31, 2021	1,000,000	100	-	-	2,968,279,672	296,828	3,952,142	739,316	(5,102)	(5,486,317)	(503,033)

						Additional		Reserve for		Cumulative				Total
		Common Stock		Paid-in		Unissued		Translation		Accumulated		Shareholders'
in USD	Notes	Number		Amount		Capital		Shares		Adjustment		Deficit		Deficit
Balance at July 31, 2020		435,482,400		43,548		1,373,074		223,219		-		(2,493,563)		(853,722)
Net loss for the interim period		-		-		-		-		-		3,040		3,040
Issuance of Common Stock for conversion of notes		919,019,645	91,902	495,233	-	-	-	587,135
Balance at October 31, 2020		1,354,502,045		135,450		1,868,307		223,219		-		(2,490,523)		(263,547)

See accompanying notes to the consolidated interim financial statements (unaudited).

5